{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T12:59:18Z","timestamp":1791896358388,"version":"4.3.4"},"reference-count":83,"publisher":"American Society of Hematology","issue":"1","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2025,1,2]]},"abstract":"<jats:sec>\n                  <jats:title>Abstract<\/jats:title>\n                  <jats:p>Early T-cell precursor acute lymphoblastic leukemia (ETP-ALL) is a unique subtype of immature T-cell ALL that was initially associated with a dramatically inferior prognosis compared with non-ETP T-cell ALL (Not-ETP) when it was first described in 2009. Analyses of larger patient cohorts treated with more contemporary regimens, however, have shown minimal survival differences between ETP and Not-ETP. In this manuscript, we use representative cases to explore therapeutic advances and address common clinical questions regarding the management of children, adolescents, and young adults with ETP-ALL. We describe our recommended treatment approach for a child or adolescent with newly diagnosed ETP-ALL, with an emphasis on the prognostic significance of induction failure and detectable minimal residual disease and the role of hematopoietic stem cell transplant in first remission. We discuss the interplay between the ETP immunophenotype and genomic markers of immaturity in T-cell ALL. Finally, we review novel therapeutic approaches that should be considered when managing relapsed or refractory ETP-ALL.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1182\/blood.2023023155","type":"journal-article","created":{"date-parts":[[2024,2,16]],"date-time":"2024-02-16T20:45:13Z","timestamp":1708116313000},"page":"43-52","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":10,"title":["How I treat ETP-ALL in children"],"prefix":"10.1182","volume":"145","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3621-8664","authenticated-orcid":false,"given":"Ryan J.","family":"Summers","sequence":"first","affiliation":[{"name":"1Department of Pediatrics, Emory University, Atlanta, GA"},{"name":"2Aflac Cancer and Blood Disorders Center, Children\u2019s Healthcare of Atlanta, Atlanta, GA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7373-8987","authenticated-orcid":false,"given":"David T.","family":"Teachey","sequence":"additional","affiliation":[{"name":"3Department of Pediatrics and the Center for Childhood Cancer Research, Children\u2019s Hospital of Philadelphia and Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5492-3957","authenticated-orcid":false,"given":"Stephen P.","family":"Hunger","sequence":"additional","affiliation":[{"name":"3Department of Pediatrics and the Center for Childhood Cancer Research, Children\u2019s Hospital of Philadelphia and Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","reference":[{"issue":"1","key":"2025010216211215500_bib1","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/j.blre.2017.08.006","article-title":"T\u00a0cell acute lymphoblastic leukemia (T-ALL): new insights into the cellular origins and infiltration mechanisms common and unique among hematologic malignancies","volume":"32","author":"Vadillo","year":"2018","journal-title":"Blood Rev"},{"issue":"2","key":"2025010216211215500_bib2","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1016\/S1470-2045(08)70314-0","article-title":"Early T-cell precursor leukaemia: a subtype of very high-risk acute lymphoblastic leukaemia","volume":"10","author":"Coustan-Smith","year":"2009","journal-title":"Lancet Oncol"},{"issue":"3","key":"2025010216211215500_bib3","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1111\/j.1365-2141.2011.08955.x","article-title":"Clinical significance of early T-cell precursor acute lymphoblastic leukaemia: results of the Tokyo Children's Cancer Study Group Study L99-15","volume":"156","author":"Inukai","year":"2012","journal-title":"Br J Haematol"},{"issue":"5","key":"2025010216211215500_bib4","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1002\/ajh.26144","article-title":"Outcome of T-cell acute lymphoblastic leukemia\/lymphoma: focus on near-ETP phenotype and differential impact of nelarabine","volume":"96","author":"Morita","year":"2021","journal-title":"Am J Hematol"},{"issue":"24","key":"2025010216211215500_bib5","doi-asserted-by":"crossref","first-page":"3816","DOI":"10.1200\/JCO.2010.28.3390","article-title":"Absence of biallelic TCRgamma deletion predicts early treatment failure in pediatric T-cell acute lymphoblastic leukemia","volume":"28","author":"Gutierrez","year":"2010","journal-title":"J\u00a0Clin Oncol"},{"issue":"4","key":"2025010216211215500_bib6","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1007\/s11684-012-0224-4","article-title":"Early T-cell precursor leukemia: a subtype of high risk childhood acute lymphoblastic leukemia","volume":"6","author":"Ma","year":"2012","journal-title":"Front Med"},{"issue":"24","key":"2025010216211215500_bib7","doi-asserted-by":"crossref","first-page":"2069","DOI":"10.1182\/blood.2023020678","article-title":"Prognostic significance of ETP phenotype and minimal residual disease in T-ALL: a Children\u2019s Oncology Group Study","volume":"142","author":"Wood","year":"2023","journal-title":"Blood"},{"issue":"21","key":"2025010216211215500_bib8","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1182\/blood.V124.21.1.1","article-title":"T-lymphoblastic leukemia (T-ALL) shows excellent outcome, lack of significance of the early thymic precursor (ETP) immunophenotype, and validation of the prognostic value of end-induction minimal residual disease (MRD) in Children\u2019s Oncology Group (COG) Study AALL0434 [abstract]","volume":"124","author":"Wood","year":"2014","journal-title":"Blood"},{"issue":"22","key":"2025010216211215500_bib9","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1182\/blood.V114.22.9.9","article-title":"Patients with early T-cell precursor (ETP) acute lymphoblastic leukemia (ALL) have high levels of minimal residual disease (MRD) at the end of induction\u2014a Children's Oncology Group (COG) Study [abstract]","volume":"114","author":"Wood","year":"2009","journal-title":"Blood"},{"issue":"6","key":"2025010216211215500_bib10","first-page":"788","article-title":"Patients with early T-cell precursor (ETP) acute lymphoblastic leukemia have high levels of minimal residual disease at the end of induction - a Children\u2019s Oncology Group (COG) study [abstract]","volume":"56","author":"Loh","year":"2010","journal-title":"Pediatr Blood Cancer"},{"issue":"2","key":"2025010216211215500_bib11","doi-asserted-by":"crossref","first-page":"e80","DOI":"10.1016\/S2352-3026(15)00254-9","article-title":"Early T-cell precursor acute lymphoblastic leukaemia in children treated in AIEOP centres with AIEOP-BFM protocols: a retrospective analysis","volume":"3","author":"Conter","year":"2016","journal-title":"Lancet Haematol"},{"issue":"3","key":"2025010216211215500_bib12","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1111\/bjh.12882","article-title":"Outcome for children and young people with early T-cell precursor acute lymphoblastic leukaemia treated on a contemporary protocol, UKALL 2003","volume":"166","author":"Patrick","year":"2014","journal-title":"Br J Haematol"},{"issue":"1","key":"2025010216211215500_bib13","doi-asserted-by":"crossref","first-page":"e28719","DOI":"10.1002\/pbc.28719","article-title":"Identification of prognostic factors in childhood T-cell acute lymphoblastic leukemia: results from DFCI ALL Consortium Protocols 05-001 and 11-001","volume":"68","author":"Burns","year":"2021","journal-title":"Pediatr Blood Cancer"},{"issue":"1","key":"2025010216211215500_bib14","doi-asserted-by":"crossref","first-page":"94","DOI":"10.3324\/haematol.2013.090233","article-title":"Immature MEF2C-dysregulated T-cell leukemia patients have an early T-cell precursor acute lymphoblastic leukemia gene signature and typically have non-rearranged T-cell receptors","volume":"99","author":"Zuurbier","year":"2014","journal-title":"Haematologica"},{"issue":"28","key":"2025010216211215500_bib15","doi-asserted-by":"crossref","first-page":"3282","DOI":"10.1200\/JCO.20.00256","article-title":"Children\u2019s Oncology Group AALL0434: a phase III randomized clinical trial testing nelarabine in newly diagnosed T-cell acute lymphoblastic leukemia","volume":"38","author":"Dunsmore","year":"2020","journal-title":"J\u00a0Clin Oncol"},{"issue":"3","key":"2025010216211215500_bib16","doi-asserted-by":"crossref","first-page":"e142","DOI":"10.1016\/S1470-2045(19)30031-2","article-title":"Comparative features and outcomes between paediatric T-cell and B-cell acute lymphoblastic leukaemia","volume":"20","author":"Teachey","year":"2019","journal-title":"Lancet Oncol"},{"issue":"9","key":"2025010216211215500_bib17","doi-asserted-by":"crossref","first-page":"1202","DOI":"10.1200\/JCO.2012.43.2070","article-title":"Postinduction dexamethasone and individualized dosing of Escherichia coli L-asparaginase each improve outcome of children and adolescents with newly diagnosed acute lymphoblastic leukemia: results from a randomized study\u2014Dana-Farber Cancer Institute ALL Consortium Protocol 00-01","volume":"31","author":"Vrooman","year":"2013","journal-title":"J\u00a0Clin Oncol"},{"issue":"2","key":"2025010216211215500_bib18","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1002\/pbc.25793","article-title":"Outcome of children with standard-risk T-lineage acute lymphoblastic leukemia\u2014comparison among different treatment strategies","volume":"63","author":"Matloub","year":"2016","journal-title":"Pediatr Blood Cancer"},{"issue":"29","key":"2025010216211215500_bib19","doi-asserted-by":"crossref","first-page":"2926","DOI":"10.1200\/JCO.2018.77.7250","article-title":"Improved survival for children and young adults with T-lineage acute lymphoblastic leukemia: results from the Children\u2019s Oncology Group AALL0434 Methotrexate Randomization","volume":"36","author":"Winter","year":"2018","journal-title":"J\u00a0Clin Oncol"},{"issue":"4","key":"2025010216211215500_bib20","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1200\/JCO.1994.12.4.740","article-title":"Treatment of childhood acute lymphoblastic leukemia: results of Dana-Farber Cancer Institute\/Children\u2019s Hospital Acute Lymphoblastic Leukemia Consortium Protocol 85-01","volume":"12","author":"Schorin","year":"1994","journal-title":"J\u00a0Clin Oncol"},{"issue":"9","key":"2025010216211215500_bib21","doi-asserted-by":"crossref","first-page":"3122","DOI":"10.1182\/blood.V84.9.3122.3122","article-title":"Chemotherapy in 998 unselected childhood acute lymphoblastic leukemia patients. Results and conclusions of the multicenter trial ALL-BFM 86","volume":"84","author":"Reiter","year":"1994","journal-title":"Blood"},{"issue":"23","key":"2025010216211215500_bib22","doi-asserted-by":"crossref","first-page":"1663","DOI":"10.1056\/NEJM199806043382304","article-title":"Augmented post-induction therapy for children with high-risk acute lymphoblastic leukemia and a slow response to initial therapy","volume":"338","author":"Nachman","year":"1998","journal-title":"N\u00a0Engl J Med"},{"issue":"5","key":"2025010216211215500_bib23","doi-asserted-by":"crossref","first-page":"2548","DOI":"10.1182\/blood-2007-02-070342","article-title":"Early postinduction intensification therapy improves survival for children and adolescents with high-risk acute lymphoblastic leukemia: a report from the Children's Oncology Group","volume":"111","author":"Seibel","year":"2008","journal-title":"Blood"},{"issue":"11","key":"2025010216211215500_bib24","doi-asserted-by":"crossref","first-page":"908","DOI":"10.1182\/blood.V112.11.908.908","article-title":"Improved outcome for children and young adults with T-cell acute lymphoblastic leukaemia (ALL): results of the United Kingdom Medical Research Council (MRC) Trial UKALL 2003 [abstract]","volume":"112","author":"Vora","year":"2008","journal-title":"Blood"},{"issue":"8","key":"2025010216211215500_bib25","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1016\/S1470-2045(14)70243-8","article-title":"Augmented post-remission therapy for a minimal residual disease-defined high-risk subgroup of children and young people with clinical standard-risk and intermediate-risk acute lymphoblastic leukaemia (UKALL 2003): a randomised controlled trial","volume":"15","author":"Vora","year":"2014","journal-title":"Lancet Oncol"},{"issue":"8","key":"2025010216211215500_bib26","doi-asserted-by":"crossref","first-page":"2077","DOI":"10.1182\/blood-2011-03-338707","article-title":"Late MRD response determines relapse risk overall and in subsets of childhood T-cell ALL: results of the AIEOP-BFM-ALL 2000 study","volume":"118","author":"Schrappe","year":"2011","journal-title":"Blood"},{"issue":"12","key":"2025010216211215500_bib27","doi-asserted-by":"crossref","first-page":"2568","DOI":"10.1038\/leu.2017.136","article-title":"JAK\/STAT pathway inhibition overcomes IL7-induced glucocorticoid resistance in a subset of human T-cell acute lymphoblastic leukemias","volume":"31","author":"Delgado-Martin","year":"2017","journal-title":"Leukemia"},{"issue":"2","key":"2025010216211215500_bib28","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1172\/JCI130189","article-title":"Glucocorticoids paradoxically facilitate steroid resistance in T cell acute lymphoblastic leukemias and thymocytes","volume":"130","author":"Meyer","year":"2020","journal-title":"J\u00a0Clin Invest"},{"issue":"7","key":"2025010216211215500_bib29","doi-asserted-by":"crossref","first-page":"e0132926","DOI":"10.1371\/journal.pone.0132926","article-title":"BCL2 inhibitor (ABT-737): a restorer of prednisolone sensitivity in early T-cell precursor-acute lymphoblastic leukemia with high MEF2C expression?","volume":"10","author":"Kawashima-Goto","year":"2015","journal-title":"PLoS One"},{"issue":"9","key":"2025010216211215500_bib30","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1007\/s11864-016-0426-0","article-title":"Long-term effect of cranial radiotherapy on pituitary-hypothalamus area in childhood acute lymphoblastic leukemia survivors","volume":"17","author":"Follin","year":"2016","journal-title":"Curr Treat Options Oncol"},{"issue":"35","key":"2025010216211215500_bib31","doi-asserted-by":"crossref","first-page":"4407","DOI":"10.1200\/JCO.2012.48.2315","article-title":"Neurocognitive outcomes decades after treatment for childhood acute lymphoblastic leukemia: a report from the St Jude Lifetime Cohort Study","volume":"31","author":"Krull","year":"2013","journal-title":"J\u00a0Clin Oncol"},{"issue":"24","key":"2025010216211215500_bib32","doi-asserted-by":"crossref","first-page":"3858","DOI":"10.1200\/JCO.2006.05.9055","article-title":"Comparison of long-term neurocognitive outcomes in young children with acute lymphoblastic leukemia treated with cranial radiation or high-dose or very high-dose intravenous methotrexate","volume":"24","author":"Spiegler","year":"2006","journal-title":"J\u00a0Clin Oncol"},{"issue":"8","key":"2025010216211215500_bib33","doi-asserted-by":"crossref","first-page":"1445","DOI":"10.1002\/pbc.26027","article-title":"Long-term social outcomes of hyperfractionated radiation on childhood ALL survivors","volume":"63","author":"Tang","year":"2016","journal-title":"Pediatr Blood Cancer"},{"issue":"12","key":"2025010216211215500_bib34","doi-asserted-by":"crossref","first-page":"2257","DOI":"10.1038\/sj.leu.2401960","article-title":"Long-term results of three randomized trials (58831, 58832, 58881) in childhood acute lymphoblastic leukemia: a CLCG-EORTC report","volume":"14","author":"Vilmer","year":"2000","journal-title":"Leukemia"},{"issue":"9","key":"2025010216211215500_bib35","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1200\/JCO.2015.64.2850","article-title":"Influence of cranial radiotherapy on outcome in children with acute lymphoblastic leukemia treated with contemporary therapy","volume":"34","author":"Vora","year":"2016","journal-title":"J\u00a0Clin Oncol"},{"issue":"26","key":"2025010216211215500_bib36","doi-asserted-by":"crossref","first-page":"2730","DOI":"10.1056\/NEJMoa0900386","article-title":"Treating childhood acute lymphoblastic leukemia without cranial irradiation","volume":"360","author":"Pui","year":"2009","journal-title":"N\u00a0Engl J Med"},{"issue":"1","key":"2025010216211215500_bib37","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1111\/j.1365-2141.2009.07853.x","article-title":"Extended triple intrathecal therapy in children with T-cell acute lymphoblastic leukaemia: a report from the Israeli National ALL-Studies","volume":"147","author":"Stark","year":"2009","journal-title":"Br J Haematol"},{"issue":"10","key":"2025010216211215500_bib38","doi-asserted-by":"crossref","first-page":"957","DOI":"10.1016\/S1470-2045(09)70228-1","article-title":"Dexamethasone-based therapy for childhood acute lymphoblastic leukaemia: results of the prospective Dutch Childhood Oncology Group (DCOG) protocol ALL-9 (1997-2004)","volume":"10","author":"Veerman","year":"2009","journal-title":"Lancet Oncol"},{"issue":"19","key":"2025010216211215500_bib39","doi-asserted-by":"crossref","first-page":"2106","DOI":"10.1200\/JCO.21.02678","article-title":"Children's Oncology Group Trial AALL1231: a phase III clinical trial testing bortezomib in newly diagnosed T-cell acute lymphoblastic leukemia and lymphoma","volume":"40","author":"Teachey","year":"2022","journal-title":"J\u00a0Clin Oncol"},{"issue":"15","key":"2025010216211215500_bib40","doi-asserted-by":"crossref","first-page":"1802","DOI":"10.1182\/blood.2022018653","article-title":"Central nervous system status is prognostic in T-cell acute lymphoblastic leukemia: a Children\u2019s Oncology Group report","volume":"141","author":"Gossai","year":"2023","journal-title":"Blood"},{"issue":"23","key":"2025010216211215500_bib41","doi-asserted-by":"crossref","first-page":"7231","DOI":"10.1182\/bloodadvances.2023011267","article-title":"Cranial radiotherapy has minimal benefit in children with central nervous system involvement in T-ALL","volume":"7","author":"O\u2019Connor","year":"2023","journal-title":"Blood Adv"},{"issue":"8617","key":"2025010216211215500_bib42","doi-asserted-by":"crossref","first-page":"921","DOI":"10.1016\/S0140-6736(88)92596-2","article-title":"Intensive therapy for children with acute lymphoblastic leukaemia and unfavourable presenting features. Early conclusions of study CCG-106 by the Childrens Cancer Study Group","volume":"2","author":"Gaynon","year":"1988","journal-title":"Lancet"},{"issue":"2","key":"2025010216211215500_bib43","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1182\/blood.2020007702","article-title":"Optimizing therapy in the modern age: differences in length of maintenance therapy in acute lymphoblastic leukemia","volume":"137","author":"Teachey","year":"2021","journal-title":"Blood"},{"issue":"3","key":"2025010216211215500_bib44","doi-asserted-by":"crossref","first-page":"802","DOI":"10.1084\/jem.162.3.802","article-title":"Early T lymphocytes. Differentiation in\u00a0vivo of adult intrathymic precursor cells","volume":"162","author":"Fowlkes","year":"1985","journal-title":"J\u00a0Exp Med"},{"issue":"12","key":"2025010216211215500_bib45","doi-asserted-by":"crossref","first-page":"2301","DOI":"10.1084\/jem.188.12.2301","article-title":"CD5 expression is developmentally regulated by T cell receptor (TCR) signals and TCR avidity","volume":"188","author":"Azzam","year":"1998","journal-title":"J\u00a0Exp Med"},{"issue":"1","key":"2025010216211215500_bib46","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/S1535-6108(02)00018-1","article-title":"Gene expression signatures define novel oncogenic pathways in T cell acute lymphoblastic leukemia","volume":"1","author":"Ferrando","year":"2002","journal-title":"Cancer Cell"},{"issue":"4","key":"2025010216211215500_bib47","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1016\/j.ccr.2011.02.008","article-title":"Integrated transcript and genome analyses reveal NKX2-1 and MEF2C as potential oncogenes in T cell acute lymphoblastic leukemia","volume":"19","author":"Homminga","year":"2011","journal-title":"Cancer Cell"},{"issue":"suppl 1","key":"2025010216211215500_bib48","doi-asserted-by":"crossref","first-page":"1727","DOI":"10.1182\/blood-2022-167157","article-title":"Comprehensive genome characterization of childhood T-ALL links oncogene activation mechanism and subtypes to prognosis [abstract]","volume":"140","author":"P\u00f6l\u00f6nen","year":"2022","journal-title":"Blood"},{"issue":"S3","key":"2025010216211215500_bib49","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1097\/01.HS9.0000843304.00278.87","article-title":"Comprehensive genome characterization reveals new subtypes and mechanisms of oncongene deregulation in childhood T-ALL","volume":"6","author":"P\u00f6l\u00f6nen","year":"2022","journal-title":"HemaSphere"},{"issue":"15","key":"2025010216211215500_bib50","doi-asserted-by":"crossref","first-page":"10008","DOI":"10.1200\/JCO.2019.37.15_suppl.10008","article-title":"Prognostic factors for survival after relapsed acute lymphoblastic leukemia (ALL): a Children\u2019s Oncology Group (COG) study","volume":"37","author":"Rheingold","year":"2019","journal-title":"J\u00a0Clin Oncol"},{"issue":"1","key":"2025010216211215500_bib51","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1182\/asheducation-2016.1.580","article-title":"T-cell acute lymphoblastic leukemia","volume":"2016","author":"Raetz","year":"2016","journal-title":"Hematology"},{"issue":"3","key":"2025010216211215500_bib52","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1182\/blood-2017-04-778829","article-title":"Oncogenetic mutations combined with MRD improve outcome prediction in pediatric T-cell acute lymphoblastic leukemia","volume":"131","author":"Petit","year":"2018","journal-title":"Blood"},{"issue":"1","key":"2025010216211215500_bib53","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1038\/leu.2015.206","article-title":"Impact of PTEN abnormalities on outcome in pediatric patients with T-cell acute lymphoblastic leukemia treated on the MRC UKALL2003 trial","volume":"30","author":"Jenkinson","year":"2016","journal-title":"Leukemia"},{"issue":"5","key":"2025010216211215500_bib54","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1111\/bjh.15449","article-title":"The presence of mutated and deleted PTEN is associated with an increased risk of relapse in childhood T cell acute lymphoblastic leukaemia treated with AIEOP-BFM ALL protocols","volume":"182","author":"Paganin","year":"2018","journal-title":"Br J Haematol"},{"issue":"7380","key":"2025010216211215500_bib55","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1038\/nature10725","article-title":"The genetic basis of early T-cell precursor acute lymphoblastic leukaemia","volume":"481","author":"Zhang","year":"2012","journal-title":"Nature"},{"issue":"8","key":"2025010216211215500_bib56","doi-asserted-by":"crossref","first-page":"1211","DOI":"10.1038\/ng.3909","article-title":"The genomic landscape of pediatric and young adult T-lineage acute lymphoblastic leukemia","volume":"49","author":"Liu","year":"2017","journal-title":"Nat Genet"},{"issue":"32","key":"2025010216211215500_bib57","doi-asserted-by":"crossref","first-page":"5025","DOI":"10.1200\/JCO.23.00088","article-title":"Outcome for children and young adults with T-cell ALL and induction failure in contemporary trials","volume":"41","author":"Raetz","year":"2023","journal-title":"J\u00a0Clin Oncol"},{"key":"2025010216211215500_bib58","doi-asserted-by":"crossref","first-page":"777108","DOI":"10.3389\/fped.2021.777108","article-title":"Minimal residual disease prior to and after haematopoietic stem cell transplantation in children and adolescents with acute lymphoblastic leukaemia: what level of negativity is relevant?","volume":"9","author":"Merli","year":"2021","journal-title":"Front Pediatr"},{"issue":"4","key":"2025010216211215500_bib59","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1111\/bjh.13160","article-title":"Increased post-induction intensification improves outcome in children and adolescents with a markedly elevated white blood cell count (\u2265200\u00a0\u00d7 109\/l) with T cell acute lymphoblastic leukaemia but not B cell disease: a report from the Children's Oncology Group","volume":"168","author":"Hastings","year":"2015","journal-title":"Br J Haematol"},{"issue":"31","key":"2025010216211215500_bib60","doi-asserted-by":"crossref","first-page":"7942","DOI":"10.1200\/JCO.2005.01.1031","article-title":"Long-term outcome in children with relapsed ALL by risk-stratified salvage therapy: results of Trial Acute Lymphoblastic Leukemia-Relapse Study of the Berlin-Frankfurt-M\u00fcnster Group 87","volume":"23","author":"Einsiedel","year":"2005","journal-title":"J\u00a0Clin Oncol"},{"issue":"4","key":"2025010216211215500_bib61","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1111\/j.1365-2141.2008.07499.x","article-title":"Long-term outcome of initially homogenously treated and relapsed childhood acute lymphoblastic leukaemia in Austria \u2013 a population-based report of the Austrian Berlin-Frankfurt-M\u00fcnster (BFM) Study Group","volume":"144","author":"Reism\u00fcller","year":"2009","journal-title":"Br J Haematol"},{"issue":"2","key":"2025010216211215500_bib62","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1111\/bjh.15919","article-title":"Bortezomib reinduction chemotherapy in high-risk ALL in first relapse: a report from the Children\u2019s Oncology Group","volume":"186","author":"Horton","year":"2019","journal-title":"Br J Haematol"},{"issue":"2","key":"2025010216211215500_bib63","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1172\/JCI130189","article-title":"Glucocorticoids paradoxically facilitate steroid resistance in T cell acute lymphoblastic leukemias and thymocytes","volume":"130","author":"Meyer","year":"2020","journal-title":"J\u00a0Clin Invest"},{"issue":"11","key":"2025010216211215500_bib64","doi-asserted-by":"crossref","first-page":"1759","DOI":"10.1182\/blood-2014-06-580480","article-title":"Efficacy of JAK\/STAT pathway inhibition in murine xenograft models of early T-cell precursor (ETP) acute lymphoblastic leukemia","volume":"125","author":"Maude","year":"2015","journal-title":"Blood"},{"issue":"9","key":"2025010216211215500_bib65","doi-asserted-by":"crossref","first-page":"1074","DOI":"10.1158\/2159-8290.CD-14-0353","article-title":"Maturation stage of T-cell acute lymphoblastic leukemia determines BCL-2 versus BCL-XL dependence and sensitivity to ABT-199","volume":"4","author":"Chonghaile","year":"2014","journal-title":"Cancer Discov"},{"issue":"24","key":"2025010216211215500_bib66","doi-asserted-by":"crossref","first-page":"6142","DOI":"10.3390\/cancers14246142","article-title":"Therapeutic targeting of MERTK and BCL-2 in T-cell and early T-precursor acute lymphoblastic leukemia","volume":"14","author":"Summers","year":"2022","journal-title":"Cancers (Basel)"},{"issue":"5","key":"2025010216211215500_bib67","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1200\/JCO.2011.34.7898","article-title":"Substantial susceptibility of chronic lymphocytic leukemia to BCL2 inhibition: results of a phase I study of navitoclax in patients with relapsed or refractory disease","volume":"30","author":"Roberts","year":"2012","journal-title":"J\u00a0Clin Oncol"},{"issue":"12","key":"2025010216211215500_bib68","doi-asserted-by":"crossref","first-page":"1149","DOI":"10.1016\/S1470-2045(10)70261-8","article-title":"Navitoclax, a targeted high-affinity inhibitor of BCL-2, in lymphoid malignancies: a phase 1 dose-escalation study of safety, pharmacokinetics, pharmacodynamics, and antitumour activity","volume":"11","author":"Wilson","year":"2010","journal-title":"Lancet Oncol"},{"issue":"6","key":"2025010216211215500_bib69","doi-asserted-by":"crossref","first-page":"1440","DOI":"10.1158\/2159-8290.CD-20-1465","article-title":"Venetoclax and navitoclax in combination with chemotherapy in patients with relapsed or refractory acute lymphoblastic leukemia and lymphoblastic lymphoma","volume":"11","author":"Pullarkat","year":"2021","journal-title":"Cancer Discov"},{"issue":"suppl 1","key":"2025010216211215500_bib70","doi-asserted-by":"crossref","first-page":"1501","DOI":"10.1182\/blood-2023-179733","article-title":"Venetoclax combined with azacitidine was effective and safe for relapsed\/refractory T-cell acute lymphoblastic leukemia\/ lymphoblastic lymphoma: preliminary results of a phase 2, multicenter trial [abstract]","volume":"142","author":"Cao","year":"2023","journal-title":"Blood"},{"issue":"11","key":"2025010216211215500_bib71","doi-asserted-by":"crossref","first-page":"e26","DOI":"10.1182\/blood-2016-09-738070","article-title":"Ex\u00a0vivo drug response profiling detects recurrent sensitivity patterns in drug-resistant acute lymphoblastic leukemia","volume":"129","author":"Frismantas","year":"2017","journal-title":"Blood"},{"issue":"3","key":"2025010216211215500_bib72","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1038\/s43018-020-00167-4","article-title":"Network-based systems pharmacology reveals heterogeneity in LCK and BCL2 signaling and therapeutic sensitivity of T-cell acute lymphoblastic leukemia","volume":"2","author":"Gocho","year":"2021","journal-title":"Nat Cancer"},{"issue":"4","key":"2025010216211215500_bib73","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1080\/1744666X.2020.1732819","article-title":"Harnessing immunotherapy for pediatric T-cell malignancies","volume":"16","author":"Diorio","year":"2020","journal-title":"Expert Rev Clin Immunol"},{"issue":"19","key":"2025010216211215500_bib74","doi-asserted-by":"crossref","first-page":"4665","DOI":"10.1182\/bloodadvances.2020002502","article-title":"CD1a is rarely expressed in pediatric or adult relapsed\/refractory T-ALL: implications for immunotherapy","volume":"4","author":"Leong","year":"2020","journal-title":"Blood Adv"},{"issue":"9","key":"2025010216211215500_bib75","doi-asserted-by":"crossref","first-page":"995","DOI":"10.1182\/blood-2017-07-794214","article-title":"Preclinical efficacy of daratumumab in T-cell acute lymphoblastic leukemia (T-ALL)","volume":"131","author":"Bride","year":"2018","journal-title":"Blood"},{"issue":"8","key":"2025010216211215500_bib76","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1182\/blood.2019000904","article-title":"Daratumumab eradicates minimal residual disease in a preclinical model of pediatric T-cell acute lymphoblastic leukemia","volume":"134","author":"Vogiatzi","year":"2019","journal-title":"Blood"},{"issue":"16","key":"2025010216211215500_bib77","doi-asserted-by":"crossref","first-page":"10001","DOI":"10.1200\/JCO.2022.40.16_suppl.10001","article-title":"Efficacy and safety of daratumumab (DARA) in pediatric and young adult patients (pts) with relapsed\/refractory T-cell acute lymphoblastic leukemia (ALL) or lymphoblastic lymphoma (LL): results from the phase 2 DELPHINUS study","volume":"40","author":"Hogan","year":"2022","journal-title":"J\u00a0Clin Oncol"},{"issue":"S3","key":"2025010216211215500_bib78","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1097\/01.HS9.0000844328.90982.61","article-title":"Efficacy and safety of daratumumab in pediatric and young adult patients with relapsed\/refractory T-cell acute lymphoblastic leukemia or lymphoblastic lymphoma: results from phase 2 Delphinus study","volume":"6","author":"Vora","year":"2022","journal-title":"HemaSphere"},{"issue":"4","key":"2025010216211215500_bib79","doi-asserted-by":"crossref","first-page":"101097","DOI":"10.1016\/j.beha.2019.101097","article-title":"Chimeric antigen receptor T cells (CAR-T) for the treatment of T-cell malignancies","volume":"32","author":"Cooper","year":"2019","journal-title":"Best Pract Res Clin Haematol"},{"issue":"1","key":"2025010216211215500_bib80","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1186\/s13045-019-0801-y","article-title":"Targeting T cell malignancies using CAR-based immunotherapy: challenges and potential solutions","volume":"12","author":"Fleischer","year":"2019","journal-title":"J\u00a0Hematol Oncol"},{"issue":"suppl 16","key":"2025010216211215500_bib81","doi-asserted-by":"crossref","first-page":"7035","DOI":"10.1200\/JCO.2022.40.16_suppl.7035","article-title":"Autologous CD7-targeted CAR T-cell therapy for refractory or relapsed T-cell acute lymphoblastic leukemia\/lymphoma","volume":"40","author":"Zhao","year":"2022","journal-title":"J\u00a0Clin Oncol"},{"issue":"30","key":"2025010216211215500_bib82","doi-asserted-by":"crossref","first-page":"3340","DOI":"10.1200\/JCO.21.00389","article-title":"Donor-derived CD7 chimeric antigen receptor T cells for T-cell acute lymphoblastic leukemia: first-in-human, phase I trial","volume":"39","author":"Pan","year":"2021","journal-title":"J\u00a0Clin Oncol"},{"issue":"12","key":"2025010216211215500_bib83","doi-asserted-by":"crossref","first-page":"1898","DOI":"10.1002\/ajh.27094","article-title":"Analysis of 60 patients with relapsed or refractory T-cell acute lymphoblastic leukemia and T-cell lymphoblastic lymphoma treated with CD7-targeted chimeric antigen receptor-T cell therapy","volume":"98","author":"Zhang","year":"2023","journal-title":"Am J Hematol"}],"container-title":["Blood"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/blood\/article-pdf\/145\/1\/43\/2349686\/blood_bld-2023-023155-c-main.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/blood\/article-pdf\/145\/1\/43\/2349686\/blood_bld-2023-023155-c-main.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,2]],"date-time":"2025-01-02T16:22:14Z","timestamp":1735834934000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/blood\/article\/145\/1\/43\/514992\/How-I-treat-ETP-ALL-in-children"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1,2]]},"references-count":83,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025,1,2]]}},"URL":"https:\/\/doi.org\/10.1182\/blood.2023023155","relation":{},"ISSN":["0006-4971","1528-0020"],"issn-type":[{"value":"0006-4971","type":"print"},{"value":"1528-0020","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,1,2]]}}}